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Background: Long-term forms of depression represent a significant mental health problem for which there is a
lack of effective evidence-based treatment. This study aims to produce findings about the effectiveness of
psychoanalytic psychotherapy in patients with treatment-resistant/treatment-refractory depression and to deepen
the understanding of this complex form of depression.
Methods/Design: INDEX GROUP: Patients with treatment resistant/treatment refractory depression. DEFINITION &
INCLUSION CRITERIA: Current major depressive disorder, 2 years history of depression, a minimum of two failed
treatment attempts, ≥14 on the HRSD or ≥21 on the BDI-II, plus complex personality and/or psycho-social
difficulties. EXCLUSION CRITERIA: Moderate or severe learning disability, psychotic illness, bipolar disorder, substance
dependency or receipt of test intervention in the previous two years. DESIGN: Pragmatic, randomised controlled
trial with qualitative and clinical components. TEST INTERVENTION: 18 months of weekly psychoanalytic
psychotherapy, manualised and fidelity-assessed using the Psychotherapy Process Q-Sort. CONTROL CONDITION:
Treatment as usual, managed by the referring practitioner. RECRUITMENT: GP referrals from primary care. RCT MAIN
OUTCOME: HRSD (with ≤14 as remission). SECONDARY OUTCOMES: depression severity (BDI-II), degree of
co-morbid disorders Axis-I and Axis-II (SCID-I and SCID-II-PQ), quality of life and functioning (GAF, CORE, Q-les-Q),
object relations (PROQ2a), Cost-effectiveness analysis (CSRI and GP medical records). FOLLOW-UP: 2 years.
Plus: a). Qualitative study of participants’ and therapists’ problem formulation, experience of treatment and of
participation in trial. (b) Narrative data from semi-structured pre/post psychodynamic interviews to produce
prototypes of responders and non-responders. (c) Clinical case-studies of sub-types of TRD and of change.
Discussion: TRD needs complex, long-term intervention and extended research follow-up for the proper evaluation
of treatment outcome. This pushes at the limits of the design of randomised therapeutic trials. We discuss some of
the consequent problems and suggest how they may be mitigated.
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Worldwide, depressive disorders have consistently been
shown to be the largest contributor to the burden of
human disease [1,2]. This is connected with the fact that
depression tends to pursue chronic or relapsing courses.
In primary care samples in the UK, 25% to 40% of
patients presenting with an index depression have at
least one further episode within the next two years; and
within 5 years, 60% will have had at least one further
episode [3]. On average, three-quarters of those who
have had a depressive illness will suffer four further epi-
sodes. While most depressive episodes tend to last about
3 months, in about 12% of patients episodes last for
longer than 2 years. These figures suggest that some-
thing like 0.7% to 1.0% of the general adult population
suffer from long-term disabling depression. Depressed
patients may also respond only partially to treatment or
may withdraw from it prematurely. Of those showing
these sub-optimal therapeutic responses, Stimpson [4]
estimated that a minimum of 30% of patients experience
recurrent treatment failures. The clinical management
problems they can pose led to the suggestion of the ex-
istence of a distinct ‘treatment-resistant’ or ‘treatment-
refractory’ form of depression. There are no findings to
suggest that a single pathogenic mechanism underlies
these difficult-to-help conditions, and the 2010 update
to the NICE Depression Guideline rejected the use of
the treatment-resistant (or treatment-refractory) diagno-
sis. Here we simply employ it as a shorthand to denote
an operationally defined, clinically significant, but het-
erogeneous group of patients.
Research evidence
These disabling, incompletely recovering and long-term
forms of depression are increasingly recognised to be a
significant mental health problem in both primary and
secondary care settings [5-10]. However until very re-
cently, there has been a shortage of research to guide
the clinical management of patients with these disorders
[4,11]. This shortage of evidence is also linked to the
way that these depressions are long-term, relapsing and
complex [12]. Co-morbidity with other common mental
disorders is the rule rather than the exception [13,14].
Difficulties with psychosocial functioning hinder import-
ant help-seeking and illness-combating behaviours:
moreover the patient’s disorder can have negative effects
on service providers and individual caregivers [15,16].
There is accumulating evidence to suggest that to be
effective, treatments for these depressions have them-
selves to be both more complex and longer than
required for simpler disorders [17]. These requirements
strain the testing capacities of randomised controlled
therapeutic trials. To determine properly the effective-
ness of a given treatment for a disorder which is bothchronic and relapsing, observation needs to be contin-
ued over a long follow-up period. This is expensive and
difficult to sustain [18]. In spite of these problems, re-
cent research has begun to bear upon the needs of
patients with these types of depression, and to examine
the complex services and treatments required [9,19-21].
Ideally, future studies should combine pragmatic rando-
mised trial designs with the exploratory possibilities
offered by qualitative research methods [22-25].
Psychoanalytic psychotherapy for depression (PPD)
PPD is a complex intervention based upon psychoanalytic
theories of the nature and origins of depression [26,27]. It
aims to help patients alter key aspects of personal func-
tioning, often connected with developmentally early
experiences of loss, to reduce an underlying depressive di-
athesis [28]. As Stiles, Shapiro and Firth-Cozens [29]
argue, the mode of action of this category of therapy is
fundamentally different from that of physical interventions
such as drugs, for which randomised controlled trials were
designed. For example, the usual dose–response algo-
rithms do not apply. However, outcome research findings
do in fact offer support for the effectiveness of psychoana-
lytically-based treatments for depression. Evidence from
RCTs indicates that short forms of psychodynamic ther-
apy may be as effective in reducing depressive symptoms
as medication or other short forms of psychological ther-
apy (for example cognitive behaviour therapy [CBT])
[20,30-33]. As well, there are cohort and observational
studies which suggest that more durable additional bene-
fits may accrue from longer-term or intensive psychoana-
lytic treatments [34-37]. These longer treatments are
based on the idea that patients are gradually able to in-
ternalise a psychological capacity which enables them to
relate to pathogenetic personal experiences, memories,
feelings, beliefs and relationships in a more reflective, yet
also more active way [38]. Findings from developmental,
observational, genetic and neuroscientific studies also
offer support for some of the main theses of the psycho-
analytic account of depression [39,40].
Over the last fifty years there has gradually developed an
adaptation of psychoanalytic ideas to a once weekly psy-
chotherapy format for use in public sector conditions.
Versions of this adaptation have been used in many UK
publicly-funded psychodynamic psychotherapy services.
Although widely adopted, their effectiveness has been
under-investigated, as is the case for all longer term psy-
chotherapies [41].
Design & methods
The hypotheses
As detailed below, the primary hypothesis is that PPD is
superior in effectiveness to a comunity treatment as usual
control group (TAU) using the Hamilton Depression
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tests the effectiveness of psychoanalytic therapy with a re-
search sample of patients suffering from TRD, as an exact-
ing test of its hypothesised ability, both to reduce
symptoms over the immediate term, and to yield signifi-
cant reductions in long-term susceptibility to depression.
The trial has been designed to test the effectiveness of the
PPD model as it might be offered in the context of an or-
dinary psychotherapy clinic, to patients with long term
mental health problems including major depression. The
aim therefore was to stay as close as possible to the setting
in which those patients with chronic TRD may be re-
ferred, and to offer the therapy in a form as little modified
as possible, while meeting what is required by trial meth-
odology. A pilot study of two cases was conducted before
commencing the study proper, to obtain information
about the practicalities of both the therapeutic and the re-
search enterprises.
We employ an intention-to-treat methodology with all
eligible, consenting participants. The participants are
randomised into two groups: one receives a target of 60
sessions of once-weekly psychoanalytic psychotherapy
for depression (PPD) over a period of eighteen months
[in practice the actual number is allowed to vary slightly
according to factors such as the timing of holidays],
while the other represents a ‘treatment as usual’ (TAU)
control condition. The PPD group is assessed over the
trial intervention and for a two year follow-up. The TAU
control group is observed over the same 3.5 year period.
The study centre
All patients attended the Adult Department of the Tavi-
stock and Portman NHS Foundation Trust in North
London, whether for measurement alone or for the test
treatment and measurement. The Department (and the
Tavistock Clinic of which it is a part) is an important
provider of psychoanalytic psychotherapy in the UK’s
publicly-funded National Health Service. The Clinic has
a distinguished record of providing human-relations and
applied psychoanalytic approaches to mental health in
the public setting. The research team are staff members
of the Tavistock and Portman’s Psychotherapy Evaluation
Research Unit (PERU). Research assessments are con-
ducted in a designated office of the Tavistock Clinic.
The sample
The definition of TRD
A patient is defined as having TRD when there has
been a minimum of 2 years’ history of depression,
assessed via SCID-I, plus at least two failed previous
attempts at treatment (elicited at interview and veri-
fied from medical records). At least one of these must
have included treatment with an antidepressant medi-
cation (ADM), and the other(s) either with an ADM,or a psychological intervention. Most patients also meet
Axis-II criteria for other diagnoses. These are assessed
using data from a clinical interview schedule - the Tavi-
stock Dynamic Interview (TDI) - an instrument primarily
concerned with representations of self and interpersonal
relationships. However, the material is suitable for the
Westen-Shedler Q-sort [42], and for the application of
DSM-5 criteria [43].
Sample size, power calculation & primary outcome
Because the analysis of the expected primary outcome is
concerned with testing superiority of PPD relative to a
comunity treatment control group (TAU), we employ
an 80% one-sided confidence interval (CI) to assess po-
tential non-inferiority. The trial is powered to detect a
35% difference in effectiveness between PPD and TAU
on the Hamilton Depression Rating Scale HRSD-17 [44]
with alpha at 0.05 and beta at 0.9. The primary outcome
for treatment efficacy is the rating of depressive symp-
toms by an objective assessor blind to treatment alloca-
tion. Estimating effect-size on the basis of previous
trials summarized in meta-analyses using the HDRS-17
in psychosocial treatments, with or without pharmaco-
logical therapies (e.g. [45]), we could achieve the target
levels of alpha and beta with 80 cases randomised equally
into two arms. However, this does not take into account
within-therapist correlations. Based on statistical analysis
of data from another trial of long term psychodynamic
therapy with a similarly heterogeneous population [46] we
have conservatively assumed an intra-cluster correlation
coefficient for therapists of 0.05. With a minimum of 10
therapists delivering each therapy, each seeing on average
5 subjects, the study will have 80% power to reject infer-
iority with a non-infidelity margin equal to an effect size
of 0.5 using an 80% one-sided confidence interval, on the
basis of a 90% follow-up rate to 6 months. Given the prag-
matic focus of the trial, the degree of adherence to treat-
ment protocols is of considerable interest. The main
analyses will be based on an intention-to-treat and com-
plementary “as treated” bases.
Recruitment & the determination of eligibility
Participants are recruited from general practitioners (GPs)
based in the Primary Care Trusts (PCTs) of central and
north London (including some PCTs on the outskirts of
these areas). In all, 425 practices have been approached,
with 119 agreeing to refer. Each is sent a pack containing
information sheets for referrers and participants, eligibility
criteria, referral forms, leaflets, and posters for the waiting
area. In addition, members of the research team visit prac-
tices to discuss the trial, TRD and the test treatment.
Participating practices then refer potential participants
whom they consider meet the eligibility criteria (see
Table 1).
Table 1 TADS Eligibility Criteria
Patient Eligibility Criteria
Inclusion Criteria Exclusion Criteria
Major Depressive Disorder or
Dysthymia
Recent (previous five years) history of
psychosis
Minimum of a two-year
history of depression
Recent (previous five year) history of
bi-polar disorder
At least two previous failed
treatment attempts, one of
which was with an
anti-depressant
Moderate or severe learning
disabilities
Age 18 – 65 Recent history (previous two years)
of psychiatric input for, or diagnosis
of, substance dependency (alcohol
abuse ≥21 units/week; drug abuse
≥ 4/week)
Able to speak conversational
English and be seen at the
Tavistock Clinic London
Patients currently in psychological
therapy
Willing to enter a
randomised control trial
Patients who have received
psychoanalytic psychotherapy in the
previous two years
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ity criteria and to confirm that these referrals in fact meet
DSM-IV criteria for Major Depressive Disorder (assessed
using the Structured Clinical Interview [SCID-I]) and
show a minimum symptom severity score of 14 on the
HRSD or 21 on the BDI-II.
Every subject meeting the criteria is then seen by an
experienced clinician, trained in psychoanalytic psycho-
therapy with adults, using the Tavistock Psychodynamic
Interview (TPI). The research aspect of the instrument
is described in detail below but it is also employed at
this stage to assess the risk of suicide or of other psychi-
atric emergencies. As well, the interviewer seeks to iden-
tify any participant in whom the stress of psychotherapy
might trigger a psychotic decompensation. Any such pa-
tient would be excluded on ethical grounds, although in
the event no subject was excluded on this basis. No se-
lection was made on the basis of any assessment of the
subjects’ presumed suitability or unsuitability for psy-
choanalytic psychotherapy.
Randomisation
The secure, automated telephone randomisation was
provided by the Clinical Trials Unit at University College
London. Minimisation is necessary to limit the impact of
factors that might moderate treatment response. A gen-
der bias has been identified in unipolar depression: UK
prevalence is estimated at 28 per 1000 in women com-
pared to 24 per 1000 in men [47]; pre-treatment severity
has been shown to affect treatment outcome [48]; and
antidepressant medications are the most frequent treat-
ment for depression. Therefore, a computer-generated,
adaptive minimisation algorithm incorporating a randomelement was employed to control for gender, depression
severity (BDI-II of 21–39 or of 40+) and medication (on/
off ). Only the information needed for the minimisation
algorithm was provided to the Clinical Trials Unit.
The test intervention
As described, the PPD intervention is 60 fifty-minute
sessions of once-weekly individual psychoanalytic psycho-
therapy. Each treatment therefore lasts for 18 months. The
therapists are all senior clinicians of the Adult Department
of the Tavistock Clinic. They have a qualification in one of
the core mental health disciplines of psychology, social
work, nursing or psychiatry, plus a British Psychoanalytic
Council approved training in psychoanalytic psychother-
apy or psychoanalysis. All therapy sessions, as well as the
therapist peer-supervision sessions, are audio-recorded.
The PPD treatment manual
Taylor [49] has written a PPD treatment manual which
describes the general principles of psychoanalytic psycho-
therapy, and the way in which they are applied to this
patient group. The manual, which states the principles that
should guide intervention, is permissive rather than pre-
scriptive in its approach. Thus it authorises trained thera-
pists to follow the direction of the patient’s narrative. In
this the manual is representative of both psychoanalytic
principles and current psychodynamic clinical practice [50].
The approach to manualisation of other evidence-based,
longer term psychodynamic therapies employs a similar
strategy [51].
As well as describing the aims and values of psychoana-
lytic treatment, the manual specifies the therapist’s tasks
and purposes in relation to the TRD patient group. It out-
lines the kind of problems and conflicts found in this pa-
tient group; it emphasises the significance of the
treatment framework, and it provides examples of session
narratives (clinical material) typically encountered in
depressed patients. The manual goes on to offer a number
of psychoanalytic formulations of the expected compo-
nents of depression, including the configurations under-
pinning chronicity and refractoriness. It illustrates the
therapeutic approaches recommended in the opening,
middle and ending phases of treatment. A specific section
is devoted to management issues likely to arise with this
patient group, including suicidal crises. The manual’s final
section identifies those features which distinguish the PPD
approach from other psychological interventions for
MDD such as CBT. The manual has been adopted in a
German multi-centre depression study [52].
The assessment of treatment fidelity
The PPD treatment is supported by fortnightly peer
supervision and therapist workshops which are audio-
recorded. The evaluation of treatment fidelity will use
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item instrument distinguishing key actions, behaviours
and therapists’ statements in different types of psycho-
logical therapy. Q-sort ratings are made according to a
pre-determined normal distribution. This approach to
the assessment of adherence has the advantage of being
independent of the theoretical model of the treatment
under evaluation. The degree of match of a given session
to a psychoanalytic prototype can be quantified [55], and
the absence of elements inimical to the test intervention
confirmed. The instrument is valid. It has been widely
used in similar investigations [56,57]. Trained raters in-
dependently score randomly selected samples of ses-
sional material on a 1 to 9 scale in terms of resemblance
to different psychological therapy prototypes. High levels
of inter-rater reliability have been achieved [57-59] We
expect the PPD treatment to score highly on the foster-
ing of unstructured open-ended dialogue, use of trans-
ference interpretations, and the identification of
unconscious processes. Low scores are expected for fea-
tures of the CBT prototype such as the negotiation of
foci on specified categories of thought and belief sys-
tems, encouragement of homework on particular issues
outside the therapy and behavioural ‘experiments’.
The treatment as usual condition
Patients randomly assigned to the TAU control group
continue to receive treatment as directed by the referring
practitioner. This may include referral for other specialist
provisions. In the UK’s NHS, the range of such treatments
is defined, and to an extent specified, in the treatment
guidelines of the National Institute for Clinical Excellence
[60]. Referral to psychoanalytic therapy is not within the
guidance. Treatments and interventions received by the
TAU control participants are recorded over the duration
of the trial by using the Client Service Receipt Inventory
(CSRI, [61]) and GP records. Arguments for and against
this kind of comparison group are considered in the Dis-
cussion. At the end of their period of participation in the
trial, the cases of all TAU participants are reviewed by the
Tavistock’s Adult Department, with a commitment to offer
PPD should it be indicated or requested.
The outcome measures
Primary outcome
In psychotherapy and antidepressant medication outcome
research, the Hamilton Rating Scale of Depression (HRSD,
[44]) is the most widely used interview-based measure of
depressive severity [62]. Independent, double-rated HRSD
scores have been chosen as the trial’s primary index of de-
pression severity. The HRSD is a structured interview
which quantifies the severity of depressive symptoms in
patients already diagnosed as suffering from depressive dis-
order. The psychometric properties of the instrument areacceptable [63]. In addition to categorical depressed/not
depressed analyses (with a score of 14 as the cut-off point
of remission), we intend to model the trajectory of scores
across the 3.5-year observation period. This will permit the
assessment of the severity of depression over time, with a
particular focus on the 2-year follow-up period.
Subsidiary outcomes
(a)Self-report depression severity: is assessed using
the Beck Depression Inventory (BDI–II [64]) which
is the most commonly used self-report instrument.
It consists of 21 items, which yield a range of scores
from 0 – 63. It has been shown to have excellent
reliability (coefficient alpha of .92 for an outpatient
population) and diagnostic efficiency [62,64].
(b)Axis I disorders: are assessed using the Structured
Clinical Interview for DSM–IV, research version
(SCID-I [65]). This semi-structured clinical interview
assesses subjects on all five axes of DSM–IV
diagnosis. The SCID-I, often considered the standard
for clinical diagnoses [66], has acceptable inter-rater
reliability (0.60 – 0.83; [67]). The diagnoses assessed
in the TADS trial are MDD, dysthymia, alcohol abuse/
dependency, drug abuse/dependency, anxiety
disorders, OCD, and eating disorders.
(c)Axis II personality disorders (PD): the Structured
Clinical Interview for DSM–IV Personality
Disorders Questionnaire (SCID-II-PQ [68]) is used
to identify patients with probable Axis II disorders.
This self-report measure has been found to have a
67% concordance with the SCID-II and strong
associations have been reported between scores on
the SCID-II and SCID-II-PQ for PD diagnostic
concepts and categories (0.74 – 0.97 [only three
under 0.80] [69]).
(d)Personality functioning: the information yielded by
the Tavistock Psychodynamic Interview (TPI) allows
Axis-II pathology to be assessed with the Shedler-
Westen Q-Sort [42]. The information also permits the
assessment of personality pathology according to the
revised criteria of the proposed DSM-5. The TPI is
described in more detail in the section below devoted
to the qualitative part of the study.
(e)Object relations: the Person’s Relating to Others
Questionnaire (PROQ2a [70]) is a 96-item self-report
questionnaire which evaluates style of personal
relating in terms of close (involving) vs. distant
(seeking separation) and upper (relating from above
downwards) vs. lower (relating from below upwards).
The measure uses eight scales which are structured
around these two axes. Birtchnell and Evans [71]
have demonstrated that all scales have high internal
validity (0.73 and above).
Table 2 Frequency of the TADS primary and secondary
outcome measures
Time point BDI HRSD CORE PROQ2 QlesQ SCID-I SCID-II-PQ CSRI
Baseline ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔
Reviews
3 Month ✔ ✔ ✔ ✔ ✔
6 Month ✔ ✔ ✔ ✔ ✔ ✔
9 Month ✔ ✔ ✔ ✔ ✔
12 Month ✔ ✔ ✔ ✔ ✔ ✔
15 Month ✔ ✔ ✔ ✔ ✔
18 Month ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔
Follow-up:
6mFU ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔
12mFU ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔
24mFU ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔
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Functioning scale (GAF, [72]) is a widely-used rating
instrument which evaluates psychological, social and
occupational functioning positioned on a hypothetical,
0 – 100 continuum of mental health - illness. It also
comprises Axis V of the DSM-IV. GAF scores are
made on the basis of the aggregated total of
information available on the subject. A treatment trial
similar to this one reported high inter-rater reliability
(0.92) [72].
(g)Subjective well-being: is assessed using the Clinical
Outcomes in Routine Evaluation – Outcome
Measure (CORE-OM [73]). This 34-item self-report
instrument assesses subjective well-being, symptoms,
function, and risk. All domains show good internal
reliability (of 0.75 – 0.95), convergent validity, and
sensitivity to change [74]. The instrument has been
widely used in the assessment of treatments offered
by UK NHS Psychotherapy Departments [41].
(h)Quality of life: the Quality of Life Enjoyment and
Satisfaction Questionnaire (Q-LES-Q [75]) is a
self-report instrument consisting of 93 items
grouped into eight quality of life areas - physical
health, subjective feelings, work, household duties,
school, leisure activities, social relationships, and
general activities. Each item is rated on a 5-point
scale of enjoyment/satisfaction over the previous
week. Mean scores can be derived from the eight
summary scales with a range from 0–100, with
higher scores indicating better quality of life. The
instrument achieves acceptable test–retest
reliability (0.60 – 0.89). Its subscales show good
levels of internal consistency (0.82 – 0.93 [76]).
(i) Number of depression-free days: at intake, and at
all subsequent review/ follow-up interviews,
participants are asked to estimate the number of
depression-free days experienced in the preceding
month
Table 2 lists all measures and the timing of their
administration.
The analysis of data
To preserve neutrality, no data will be analysed until all
subjects have reached the six month follow-up point. An
intention-to-treat analysis will be performed in the first in-
stance (i.e. analysing all available data from randomised
participants) using for all analyses the STATA, version 11.0
package. The numbers and percentages of losses to follow-
up at 12, 18, and 24 months after randomisation will be
reported and will be compared between the treatment
arms with absolute risk differences (95% CIs). Any deaths
and their causes will be separately reported. To increase
the power and precision of the estimated treatment effect,missing baseline covariates will be imputed for our main
analysis using either mean or regression imputation [77].
All available results will be used without missing outcomes
being imputed. Primary analyses will be based on the as-
sumption of ignorable drop-outs. In secondary analyses,
missing values will be replaced by multiple imputations
using Markoff Chain Monte Carlo methods [78].
For continuous outcome variables, the differences in
mean score between those randomised to either arm of the
trial will be examined using analysis of covariance adjusting
by 1) baseline value of outcome 2) baseline value of the
outcome, gender and age. The assumption of linearity will
be assessed by residual analysis; if necessary, bootstrapping
techniques will be employed. Sensitivity analyses will be
conducted to take into account missing data using multiple
imputation, which assumes data are 'missing at random'.
For continuous response variables, statistical analyses will
be based on linear mixed models [79].
For binary responses, mixed-model logistic regression
models and generalized estimating equations will be
used [80]. Logistic regression will be used to compare
proportions of patients that have lost their diagnosis
during the treatment and follow-up period in the two
groups using an HRSD of 14 as criterion. Analysis of
'time to first recovery' and ‘time to first relapse’ outcome
will also be conducted using survival analysis methods
and the log-rank test for bivariate comparisons and
Cox's proportional hazards to adjust for gender, stratifi-
cation variables and time spent on treatment prior to
randomisation. The dependencies between design points
in the case of linear mixed models will be accounted for
by assuming an unstructured correlation structure.
Statistical significance will be tested with the Wald
test, and CIs will be established by the Delta method
[81]. Time will be handled as a categorical variable with
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model will include the main effects of time, of treatment
group, of the difference between theoretical and realised
date of measurement and first order interaction of time
and treatment. A complete model will include potential
confounding factors (e.g. age group, gender etc). Com-
plementary analyses will be carried out adjusting for the
baseline level of outcome measures. 'As treated' models
will be carried out by including variables describing
compliance (e.g. waiting time from randomisation to ini-
tiation, degree of participation, including an indicator
whether the patient received the study treatment) and
auxiliary treatments such as medication.
Economic evaluation
The exact number of therapy sessions is recorded. Costs of
these will be estimated using data on staff salaries, over-
heads and activity levels. Use of other services during the
12-month period before baseline and during the follow-up
(broken down into six-month periods) is measured with
the Client Service Receipt Inventory (CSRI, [61]) which
asks for information on the number and duration of con-
tacts with primary and secondary health and social care
professionals, and time lost from work. Service costs are
calculated by combining the service use data with standard
unit costs [61,82]. Lost employment costs will be calculated
by combining time off work with average wage rates. Ac-
cess to medical notes is agreed. These will be used to
supplement CSRI data. Given that under-reporting of ser-
vice use is more likely than over-reporting, we will use the
higher number of contacts with clinicians if the two sources
differ. Cost-effectiveness will be assessed by combining cost
data with the HRSD change score: incremental cost-
effectiveness ratios will be computed to show the extra cost
incurred to achieve a one-unit improvement on the HRSD;
uncertainty around these estimates will be addressed using
cost-effectiveness planes. These analyses will be conducted
first for healthcare costs and then for total costs (i.e. use of
other services and lost employment). Sensitivity analyses
will be conducted by increasing/decreasing the therapy
costs by 25% and by using minimum wage rates to value
lost employment.
Qualitative & psychoanalytic case-study
evaluation
The private theories of participant and therapist
The Private Theories Interview (PTI, [83]) has been used in
the investigation of patients’ views of illness and treatment
response [84-86]. The imposition of the researcher’s con-
structions is minimised to permit the interviewee’s views to
emerge. Here, we use this semi-structured interview to col-
lect narrative material relevant to participants’ theories
about their depression, their experience of treatment and of
participation in a long-term, randomised trial such as this.This is done with a purposive sub-sample drawn from both
patient groups and in the case of the PPD arm, with the
corresponding therapists. The sample will also be matched
for age, sex, demographics and treatment-response (com-
pleters versus drop-outs; and responders, intermediate or
non-responders). Analysis is systematic and follows a cod-
ing manual [83] organised around the phenomenological
principles of “categorization of meaning” and “concentra-
tion on meaning” [87]. Subsequent analyses will be con-
cerned with the subject’s perspective on any therapeutic
change and any associations between participants’ views
and the quantitative outcome measures.
The Tavistock psychodynamic interview (TPI)
The TPI is a specially designed instrument [88] adminis-
tered by a trained psychoanalytic clinician. It draws on well
validated psychodynamic and attachment-based interviews.
These are the Adult Attachment Interview (AAI; [2]), the
Current Relationships Interview (CRI; [89]), and the Quality
of Object Relating Scale (QORS; [90]). The AAI [91], is
based upon the way that the formal quality of adult dis-
course has been found to be lawfully related to attachment
patterns established in early development. There is strong
evidence for thematic continuity between narratives,
dreams, early autobiographical memories and attachment
patterns [92]. The CRI and the QORS both aim to assess
the quality of object relationships and have been shown to
have good validity [93].
The interview is carried out at the subject’s entry to the
trial (TDI-Initial) and repeated two years later (i.e. six
months after the end of therapy in the case of patients in
the PPD condition). In addition to the clinical and person-
ality assessment functions already described, the TPI col-
lects narrative data about subjects' relationship histories.
Particular attention is paid to key developmental and tran-
sitional phases in early childhood, adolescence, adulthood.
Subjects are asked to relate a recent dream and their
earliest memory. The aim is to capture subjects’ repre-
sentations of key interpersonal relationships along with
psychodynamically important aspects of cognitive and
emotional processing, to arrive at an independent psy-
chodynamic formulation of the subject’s illness.
The end version of the TDI looks for changes in the psy-
chological and interpersonal functions which according to
psychoanalytic thinking play a part in depressive disorders.
Any changes in personal narratives or in functioning across
the domains of early and later relationships, work, physical
health, etc. are noted. The initial interview’s request for a
recent dream and an earliest childhood memory is
repeated verbatim to compare participants’ responses at
the different time points. Independent judges will then cat-
egorise subjects as responders, intermediate or non-
responders in terms of these psychodynamic variables. This
categorisation will then be correlated with treatment
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will delineate prototypes to examine the possibility of dif-
ferent constellations of illness, types of vulnerability and
different patterns of responsiveness/non-responsiveness.Psychoanalytic case-study methods
Here we detail three sub-studies based on psychoanalytic
theory, and which use case-study methods. They are
designed to provide a general model which may help ex-
plain the RCT findings, and to probe specific questions.A psychoanalytic typology of different forms of chronic
depression Applying the ideas of Rosenfeld [94], Blatt
[95], Blatt & Zuroff [96] and Bleichmar [97], along with
the preliminary clinical investigation of five pilot cases, a
provisional typology consisting of seven components/
dimensions has been constructed [98,99]. A purposive
sub-sample drawn from the patients in the PPD arm
(N = 67) will be selected by members of the clinical re-
search workshops to include the full range of the most
frequently encountered sub-forms of TRD, plus any
exceptions, extreme types or others thought to be espe-
cially informative [100,101]. It will contain a minimum
of 25 cases. On the basis of extended clinical discussions
of therapists’ verbal session reports over the course of
the subjects’ treatments, plus transcripts of audio-
recordings, an evaluating group of therapists will assess
the model’s fit, and its ability to make sense of the het-
erogeneity in the sample. Each subject will then be
described along with a proforma ‘rating’ based upon the
typology. The research group’s consensus and descrip-
tion will be checked against the therapist’s judgement,
and if necessary will be modified by it (see [102,103]).
The original accounts of the sub-set and the typology
descriptions will be compared and checked against the
therapists’ experience of the whole PPD sample. Any
modifications of the model which seem to be required
will then be set out. The aim throughout will be to pro-
vide ‘thick descriptions’, each of which will be referenced
to the different kinds of information used.The nature of change or non-change in PPD treated
patients Using a similar approach a subset of the PPD
arm will be selected to include a full range of outcome cat-
egories - responders, non-responders, intermediate and
treatment failures - determined on the basis of therapists’
clinical judgements. Therapists will then provide ‘thick
descriptions’, again referenced to the information used, to
detail the elements of the positive or negative change oc-
curring. These descriptions will be employed with the
quantitative findings and the TPI to triangulate a more
three-dimensional picture of different outcomes.Investigating the possible role of an increased sense of
personal agency in PPD responders, and of persisting
passivity in non-responders There is evidence that a
sense of personal agency [104], as one part of the execu-
tive function of the personality [105] plays an important
part in mental health [106,107], in developmental or social
resilience [108], and in recovery from mental disorder. In
the case of depression, variations in psychosocial function-
ality correlate poorly with symptom severity and variations
in motivation cannot be accounted for on the basis of
mood alone. Psychoanalytic findings suggest that persist-
ent forms of passivity, which may also be encountered in
subjects with TRD, may militate against treatment re-
sponse [109,110]. In this part of the qualitative study, the
therapist selected sample of responders, non-responders,
intermediate and treatment failures described above will
be evaluated in terms of a psychoanalytic conceptualisa-
tion of personal agency devised by Amino & Taylor (2008,
unpublished).Ethical approval
The trial received ethical approval from the NHS West
Midlands Research Ethics Committee on 28 May 2002 –
reference number MREC02/07/035. Amendments were
approved in July 2005, October 2009, and February 2010.
Some of the ethical issues encountered in the conduct of
this long-term trial are considered in the Discussion below.
Trial progress and participant recruitment. See:
(Additional file 1: Figure S1).Discussion
This pragmatic RCT is notable in that through a high-
quality design it evaluates a previously under-researched
treatment, namely medium to long-term psychoanalytic
psychotherapy, which aims to reduce the underlying vul-
nerability to depression in people suffering from a par-
ticularly complex and enduring form of this disorder.
Currently, there is only one trial with a group of patients
of a roughly comparable complexity [111-114]. A posi-
tive finding in our trial would significantly improve the
options available for patients with this expensive and
relatively poorly-served condition, which also represents
a considerable burden worldwide [60,115].
However, as we have argued, the features of both the
disorder and the treatment strain the limits of method-
ology in classical randomised clinical trials. We decided
that the trial should be ecological, namely that it ought to
offer information about the actual outcome over the
medium to long-term of a clinically significant patient
sample in the NHS. Many of the trial’s design choices fol-
lowed from this decision. In this section, we discuss how
we have tried to mitigate some of the strains, and list some
inevitable limitations.
Taylor et al. BMC Psychiatry 2012, 12:60 Page 9 of 13
http://www.biomedcentral.com/1471-244X/12/60The patient sample
In relation to the diagnosis of depressive and other com-
mon mental disorders, we do not yet know how to carve
nature at the joints. If our study were to meet its pri-
mary requirement of ecological validity, the sample
selected had to involve the fewest possible assumptions.
We therefore defined the sample operationally, and
included participants with co-morbid Axis I and II disor-
ders as well as problems with physical health. Inevitably,
this leads to a heterogeneous sample that includes many
unknown variations capable of affecting both outcome
and the interpretation of findings. Although PPD has the
advantage as a treatment of being adaptable to each
individual’s psychopathology, we still expect a large
amount of residual variation in responsiveness amongst
different patients. The treatment under test will help
some participants more than others, and these variations
may cancel each other out [116]. In this context, exam-
ining mean outcomes, for example, will be insufficient,
and while modelling trajectories of outcomes using
mixed-effects growth curves allows for differential treat-
ment responses to be investigated, this is only possible
when the critical moderators involved first have been
identified and then measured. In the absence of predic-
tions derived from well-founded theories of pathology,
this is a hit or miss way of proceeding. The poor per-
formance of outcome research in answering the question
“what works for whom?” suggests that this approach
might be misconceived [117]. It may be necessary to be
able to drill down through group data to discover what
may be deeper structures in the individual in order to
understand the basis of differential degrees of respon-
siveness/non-responsiveness. Thus we have collected
qualitative data using both psychoanalytic and phenom-
enological methods.
The treatment as usual condition
A TAU control condition was chosen because it is an
ecologically sound comparison group. TAU control con-
ditions have been widely used in outcome trials, al-
though their rationale, and what any given TAU
condition may involve, has varied from case to case
[25]. Our TAU control condition is only partly deter-
mined by the management protocols for these patients
specified in NICE guidelines. In actual practice, there
are widespread variations in the mental health resources
available in different locations (NHS Atlas) and, in our
experience, these are especially marked in the treatment
that TRD patients receive. Some may receive exemplary
care through their GPs, including social support, com-
munity mental health teams, brief counselling, and
pharmacological and psychological interventions of ap-
propriate types, durations and intensities. Others may
get little if any help beyond token pharmacologicaltreatment, with little case management. Some, perhaps
following many failed attempts at treatment, may have
withdrawn from all treatment endeavours. They feel
they have exhausted all treatment possibilities and end
up quite seriously neglected and deprived. As we have
also suggested, certain characteristic features of psycho-
social functioning may be integral to the TRD disorder.
By adversely affecting important help-seeking beha-
viours, these actively exert negative effects on service
provisions. These considerations lend weight to the de-
cision to study this naturally occurring control and
comparison condition [118].
A long-term trial involving patients with severe de-
pressive disorders operates against a background of a
continuous level of chronic suicidal risk punctuated
by exacerbations and crises. Our guiding principle is
that the TAU participant’s clinical needs must always
come first. The senior research clinician and the
trial’s clinical director explicitly assume responsibility
for participants’ safety and have the authority to inter-
vene and mediate in a participant’s care. In most
instances this does not conflict with one of the needs
of research - for instance, to keep as many subjects
in the trial as possible for as long as possible. How-
ever, it follows that the trial’s TAU condition is not
always and not only Treatment As Usual. Moreover,
the consistent, reliable contact involved in the
researcher’s administration of research measures ne-
cessarily functions like a low-intensity, psychodynam-
ically informed supportive intervention.
Randomisation
TRD participants vary in their resilience to the significant
stresses that research involves. One of the most potent
stresses is randomisation powerfully stirs up feelings of re-
jection especially in those who already have histories of se-
vere loss or abandonment. Subjects who had strong wishes
for the PPD treatment feel disappointed, hurt or angry
when the allocation is not that for which they hoped. These
subjects may then drop-out. Others drop out because of
their fears about what treatment may involve. When parti-
cipants are told of their treatment allocation, it is important
that the research staff show sensitivity to the situation. The
psychoanalytically-trained research clinicians allow space in
the initial clinical interview for the subject to express how
they felt about the allocation they received. As well, the re-
search clinician has to be mindful of the underlying feelings
aroused by the long research process especially with those
who were randomised to the TAU control.
The need for best research practice
Over the longer-than-usual time of this trial, we consid-
ered there might be a greater tendency for subjects to
drop out. To combat this, continuity and absolute best
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Researchers needed to be reliable, persistent, flexible,
sympathetic and responsive with all the subjects. News-
letters and other communications about the trial can be
used to help subjects remain aware of the fact that they
are helping in a valuable endeavour.
However, most research staff are not clinically qualified
and are often at the beginnings of their career. It is there-
fore essential that these research staff are provided with
sufficient clinical supervision by qualified research clini-
cians. The supervision has three functions. First, it gives
the research staff a chance to process the considerable
emotional impact associated with the way that subjects
often powerfully convey their feelings. Second, it helps
researchers to reconcile subjects’ ongoing communication
of their needs with the researcher’s task of equipoise, while
still helping subjects stay in the trial. Third, it gives the re-
search clinician an opportunity to keep in touch with each
patient’s condition.
The limitations of the trial
When compared with other long-term psychoanalytic psy-
chotherapy (LTPP) outcome studies our N of 129 may be
regarded as large, but considered statistically the trial is
somewhat under-powered. Unfortunately, the very large
and expensive treatment service resources necessary for a
significantly bigger sample are simply not available. A
second limitation is to be found in the impossibility of con-
cealing treatment allocation from research interviewers.
We seek to mitigate this by double-rating the primary out-
come measure using independent raters working with
anonymised recordings. Another limitation is the inherent
variability both of our test treatment and of the TAU com-
parison condition. Although our design includes a treat-
ment manual, assessment of adherence, and careful
recording of the TAU care control patients actually receive
this still does not permit the kind of quasi-experimental as-
sessment of the impact of the components that are possible
with less complex treatment procedures. Finally, in a long-
term trial with patients of this kind the inevitably high rate
of attrition could easily cause a statistically unacceptable
standard mean error [119].
In this discussion we have considered only some of
the issues in long-term randomised trials of complex
treatments for complex mental health conditions. We
opted for this composite, ecological design as a first
stage study in which a standard RCT was complemen-
ted by evaluative methods in order to produce in-depth
models helpful in understanding the condition itself, as
well as with the development of more optimal treat-
ment and case management. We want to emphasise the
importance of research procedures capable of meeting
the challenges posed by the disorder. Some knowledge
of the complex nature of the disorder is also necessaryto properly evaluate both the structure of the research,
and its eventual findings.
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